Tiger Brokers

BUZZ-Beam Therapeutics rises on early-stage trial results for gene editing therapy

Reuters
Mar 10, 2025
BUZZ-Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on early-stage trial results for gene editing therapy

** Biotech firm Beam Therapeutics' BEAM.O shares rise 9.7% to $31.24 premarket

** BEAM says its experimental gene-editing therapy, BEAM-302, surpassed theoretical threshold for efficacy with the third dose level of 60 mg of the therapy

** Three patients received the 60 mg dose in an early-stage study to treat Alpha-1 antitrypsin deficiency (AATD)

** AATD is a genetic disorder that occurs when the body doesn't produce enough of the AAT protein which protects lungs and liver

** There is a clear path forward for BEAM-302 - brokerage BMO Capital Markets

** Co plans to continue testing higher doses in the ongoing study, expects to report further data in H2 2025

** BEAM has fallen 23% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10